Recruiting

EMVision emu™ Brain Scanner

Sponsor:

EMVision Medical Devices Ltd

Code:

NCT06999122

Conditions

Stroke

Hemorrhagic Stroke

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

Brain Scan

Study Details

Brief summary:

The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available.

EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.

Conditions

Stroke

Hemorrhagic Stroke

Study ID

NCT06999122

Start date

Mar 26, 2025

Status verified date

Jul, 2026

Completion date

Nov 28, 2026

Anticipated

Primary completion date

Nov 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Adults ≥22 years of age
2. Observable acute neurological deficit suspected to be stroke and within 24 hours of symptom onset
3. The use of the EMVision emu™ Brain Scanner will not delay the treatment of the patient
4. CT or MRI brain imaging following clinical evaluation per standard of care
5. Head size deemed suitable for scanning with the EMVision emu™ Brain Scanner -

Exclusion Criteria:

1. Has received treatment for current (suspected) stroke event prior to initial CT/MRI scan OR EMVision emu™ Brain Scanner scan (such as thrombolysis)
2. In-patient for a neurological condition prior to suspected stroke onset
3. In-patient in intensive care unit prior to suspected stroke onset
4. Contraindication to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and/or angiography
5. Presence of any implanted electro-stimulating devices in the head and neck
6. Presence of any metallic implants in the cranial vault or surrounding bones/tissue (Note that metallic objects distant from the scan area, such as dental implants, nasal piercing etc., are acceptable)
7. Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device
8. Inability to wear the investigational device (skin lesions on scalp, obvious recent blunt or penetrating injury to head, previous intracranial surgeries, neck injury etc.)
9. Unable to lie still for the duration of the scan
10. Pregnant or breastfeeding
11. Any other condition or symptoms preventing the participant from entering the study, according to the investigator´s judgment -

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Arms

Intracranial Haemorrhage Group A

Other Group B

Group B includes all patients enrolled in the study ultimately diagnosed with a condition other than intracranial haemorrhage, including ischaemic stroke, transient ischaemic attack, or any of a variety of stroke mimicking conditions.

Interventions

Brain Scan

The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head.

The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues.

Primary outcome measure

  • Demonstrate haemorrhage detection sensitivity >80% and specificity >80% [ Time Frame: <30 minutes from acute baseline CT/MRI ]

Central Contacts and Locations

Central contacts

Locations

UCLA

Recruiting

Los Angeles, California, United States, 90095

Contacts

Principal Investigator:

May Nour, MD, PHD

Mayo Jacksonville

Recruiting

Jacksonville, Florida, United States, 32224

Contacts

Principal Investigator:

William Freeman, PhD

Mount Sinai West

Recruiting

New York, New York, United States, 10019

Contacts

Principal Investigator:

Hazem Shoirah, MD

Mount Sinai Health System

Recruiting

New York, New York, United States, 10029

Contacts

Principal Investigator:

Hazem Shoirah, MD

Memorial Hermann Memorial City Medical Center

Recruiting

Houston, Texas, United States, 77024

Contacts

Principal Investigator:

Aaron M Gusdon, PhD

UTHealth

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Aaron Gusdon, PhD

More Information

Sponsor

EMVision Medical Devices Ltd

Last update posted

Jul 27, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-08. This information was provided to ClinicalTrials.gov by EMVision Medical Devices Ltd on 2026-07-27. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.